Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD.
Aged
Aged, 80 and over
Brain Ischemia
/ diagnosis
Drug Prescriptions
Drug Utilization
/ trends
Dyslipidemias
/ diagnosis
Female
Healthcare Disparities
/ trends
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ adverse effects
Male
Medication Adherence
Middle Aged
Peripheral Arterial Disease
/ diagnosis
Practice Patterns, Physicians'
/ trends
Risk Assessment
Risk Factors
Sex Factors
Time Factors
Treatment Outcome
United States
/ epidemiology
Veterans Health
Adherence
Gender disparities
ICVD
PAD
Prescription rates
Statin
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
17
08
2020
pubmed:
26
8
2020
medline:
9
6
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
This study sought to investigate gender-based disparities in statin prescription rates and adherence among patients with peripheral arterial disease (PAD) and ischemic cerebrovascular disease (ICVD). We identified patients with PAD or ICVD seeking primary care between 2013 and 2014 in the VA healthcare system. We assessed any statin use, high-intensity statin (HIS) use, and statin adherence among women with PAD or ICVD compared with men. We also compared proportion of days covered (PDC) as a measure of statin adherence; PDC ≥ 0.8 deemed a patient statin adherent. Association between statin use (or adherence) and odds of death or myocardial infarction (MI) at 12-month follow-up was also ascertained. Our analyses included 192,219 males and 3188 females with PAD and 331,352 males and 10,490 females with ICVD. Women with PAD had lower prescription rates of any statin (68.5% vs. 78.7%, OR 0.68, 95% confidence interval (CI) 0.62-0.75), HIS (21.1% vs. 23.7%, OR 0.88, 95% CI 0.79-0.97), and lower statin adherence (PDC ≥ 0.8: 34.6% vs. 45.5%, OR 0.75, 95% CI 0.69-0.82) compared with men. Similar disparities were seen in ICVD patients. Among female patients with PAD or ICVD, statin adherence was associated with lower odds of MI (OR 0.76, 95% CI 0.59-0.98), while use of any statin (OR 0.71, 95% CI 0.56-0.91) and HIS (OR 0.68, 95% CI 0.48-0.97) was associated with lower odds of death at 12 months. Women with PAD or ICVD had lower odds of receiving any statins, HIS, or being statin adherent. Targeted clinician- and patient-level interventions are needed to study and address these disparities among patients with PAD and ICVD.
Identifiants
pubmed: 32840709
doi: 10.1007/s10557-020-07057-y
pii: 10.1007/s10557-020-07057-y
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM